Buchumschlag

Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery

Monoclonal antibodies (mAbs) are increasingly exploited as vehicles for the targeted delivery of cytotoxic drugs. In antibody-drug conjugates (ADCs) antibodies specifically deliver cytotoxic compounds to cancer cells. Here, we present a technology for elevating the intracellular delivery of antibodi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sauter, Max (VerfasserIn) , Strieker, Matthias (VerfasserIn) , Kleist, Christian (VerfasserIn) , Wischnjow, Artjom (VerfasserIn) , Daniel, Volker (VerfasserIn) , Altmann, Annette (VerfasserIn) , Haberkorn, Uwe (VerfasserIn) , Mier, Walter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 14 March 2020
In: Journal of controlled release
Year: 2020, Jahrgang: 322, Pages: 200-208
ISSN:1873-4995
DOI:10.1016/j.jconrel.2020.03.005
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jconrel.2020.03.005
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0168365920301541
Volltext
Verfasserangaben:Max Sauter, Matthias Strieker, Christian Kleist, Artjom Wischnjow, Volker Daniel, Annette Altmann, Uwe Haberkorn, Walter Mier
Beschreibung
Zusammenfassung:Monoclonal antibodies (mAbs) are increasingly exploited as vehicles for the targeted delivery of cytotoxic drugs. In antibody-drug conjugates (ADCs) antibodies specifically deliver cytotoxic compounds to cancer cells. Here, we present a technology for elevating the intracellular delivery of antibodies by the conjugation of tetrameric cell-penetrating peptides (tCPPs). The solid phase synthesis of tCPPs and their application in a chemical modification strategy for mAbs provides constructs that attain up to fourfold elevated internalization rates while retaining the mAbs target specificity. The antigen independent internalization is accompanied by beneficial pharmacokinetics limiting off-target accumulation. Applicability was proven for matuzumab, trastuzumab and the ADC Kadcyla®. Cytotoxicity studies of tCPP-conjugates of Kadcyla® resulted in a sixfold increased cytotoxicity proving the potential of chemical modification strategies to extend the applicability of biologicals. This constitutes a significant step towards next-generation antibody-based therapeutics.
Beschreibung:Gesehen am 22.03.2021
Beschreibung:Online Resource
ISSN:1873-4995
DOI:10.1016/j.jconrel.2020.03.005

Ähnliche Einträge